Suppr超能文献

一种用于肾上腺皮质癌的新型 T 分期分类系统:来自美国肾上腺皮质癌研究组的建议。

A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group.

机构信息

Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA.

出版信息

Ann Surg Oncol. 2018 Feb;25(2):520-527. doi: 10.1245/s10434-017-6236-1. Epub 2017 Nov 21.

Abstract

BACKGROUND

The 7th AJCC T-stage system for adrenocortical carcinoma (ACC), based on size and extra-adrenal invasion, does not adequately stratify patients by survival. Lymphovascular invasion (LVI) is a known poor prognostic factor. We propose a novel T-stage system that incorporates LVI to better risk-stratify patients undergoing resection for ACC.

METHOD

Patients undergoing curative-intent resections for ACC from 1993 to 2014 at 13 institutions comprising the US ACC Group were included. Primary outcome was disease-specific survival (DSS).

RESULTS

Of the 265 patients with ACC, 149 were included for analysis. The current T-stage system failed to differentiate patients with T2 versus T3 disease (p = 0.10). Presence of LVI was associated with worse DSS versus no LVI (36 mo vs. 168 mo; p = 0.001). After accounting for the individual components of the current T-stage system (size, extra-adrenal invasion), LVI remained a poor prognostic factor on multivariable analysis (hazard ratio 2.14, 95% confidence interval 1.05-4.38, p = 0.04). LVI positivity further stratified patients with T2 and T3 disease (T2: 37 mo vs. median not reached; T3: 36 mo vs. 96 mo; p = 0.03) but did not influence survival in patients with T1 or T4 disease. By incorporating LVI, a new T-stage classification system was created: [T1: ≤ 5 cm, (-)local invasion, (+/-)LVI; T2: > 5 cm, (-)local invasion, (-)LVI OR any size, (+)local invasion, (-)LVI; T3: > 5 cm, (-)local invasion, (+)LVI OR any size, (+)local invasion, (+)LVI; T4: any size, (+)adjacent organ invasion, (+/-)LVI]. Each progressive new T-stage group was associated with worse median DSS (T1: 167 mo; T2: 96 mo; T3: 37 mo; T4: 15 mo; p < 0.001).

CONCLUSIONS

Compared with the current T-stage system, the proposed T-stage system, which incorporates LVI, better differentiates T2 and T3 disease and accurately stratifies patients by disease-specific survival. If externally validated, this T-stage classification should be considered for future AJCC staging systems.

摘要

背景

基于大小和肾上腺外侵犯的第 7 版 AJCC T 分期系统不能充分根据生存情况对肾上腺皮质癌 (ACC) 患者进行分层。淋巴管侵犯 (LVI) 是已知的不良预后因素。我们提出了一种新的 T 分期系统,该系统将 LVI 纳入其中,以更好地对接受 ACC 切除术的患者进行风险分层。

方法

纳入了 1993 年至 2014 年在美国 ACC 小组 13 个机构接受根治性切除术的 ACC 患者。主要结局是疾病特异性生存 (DSS)。

结果

在 265 例 ACC 患者中,有 149 例进行了分析。当前的 T 分期系统无法区分 T2 与 T3 期疾病 (p=0.10)。存在 LVI 与无 LVI 相比,DSS 更差 (36 个月 vs. 168 个月;p=0.001)。在考虑当前 T 分期系统的各个组成部分 (大小、肾上腺外侵犯) 后,LVI 在多变量分析中仍然是一个不良预后因素 (风险比 2.14,95%置信区间 1.05-4.38,p=0.04)。LVI 阳性进一步分层了 T2 和 T3 期疾病患者 (T2:37 个月 vs. 中位数未达到;T3:36 个月 vs. 96 个月;p=0.03),但对 T1 或 T4 期疾病患者的生存无影响。通过纳入 LVI,创建了一个新的 T 分期分类系统:[T1:≤5cm,(-)局部侵犯,(+)/-LVI;T2:>5cm,(-)局部侵犯,(-)LVI 或任何大小,(+)局部侵犯,(-)LVI;T3:>5cm,(-)局部侵犯,(+)LVI 或任何大小,(+)局部侵犯,(+)LVI;T4:任何大小,(+)邻近器官侵犯,(+)/-LVI]。每个新的 T 分期组的中位 DSS 均较差 (T1:167 个月;T2:96 个月;T3:37 个月;T4:15 个月;p<0.001)。

结论

与当前的 T 分期系统相比,新提出的 T 分期系统将 LVI 纳入其中,可更好地区分 T2 和 T3 期疾病,并准确根据疾病特异性生存情况对患者进行分层。如果外部验证成功,该 T 分期分类系统应考虑纳入未来的 AJCC 分期系统。

相似文献

1
A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group.
Ann Surg Oncol. 2018 Feb;25(2):520-527. doi: 10.1245/s10434-017-6236-1. Epub 2017 Nov 21.
4
Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence.
Ann Surg Oncol. 2016 Jan;23(1):126-33. doi: 10.1245/s10434-015-4810-y. Epub 2015 Aug 18.
6
A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease.
Surgery. 2014 Dec;156(6):1378-85; discussion 1385-6. doi: 10.1016/j.surg.2014.08.018. Epub 2014 Nov 11.
8
Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.
Lung Cancer. 2018 Nov;125:245-252. doi: 10.1016/j.lungcan.2018.09.024. Epub 2018 Oct 1.
10
Adrenocortical carcinoma surgery-surgical extent and approach.
Langenbecks Arch Surg. 2016 Nov;401(7):991-997. doi: 10.1007/s00423-016-1462-8. Epub 2016 Jul 13.

本文引用的文献

4
Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
J Am Coll Surg. 2016 Apr;222(4):480-90. doi: 10.1016/j.jamcollsurg.2015.12.013. Epub 2015 Dec 21.
6
Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment.
Front Cell Dev Biol. 2015 Jul 3;3:45. doi: 10.3389/fcell.2015.00045. eCollection 2015.
8
Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease.
Surgery. 2014 Dec;156(6):1531-40; discussion 1540-1. doi: 10.1016/j.surg.2014.08.047. Epub 2014 Nov 11.
9
A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease.
Surgery. 2014 Dec;156(6):1378-85; discussion 1385-6. doi: 10.1016/j.surg.2014.08.018. Epub 2014 Nov 11.
10
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.
Eur J Endocrinol. 2013 Oct 23;169(6):891-899. doi: 10.1530/EJE-13-0519. Print 2013 Dec.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验